# GLP-1 Number Needed to Treat: 66 for One Major Cardiovascular Event

See what a number needed to treat of 66 means for GLP-1 cardiovascular outcomes, including how baseline risk and follow-up affect the estimate.

Publisher: Buy This GLP Editorial Team
Canonical: https://buythisglp.com/research/glp1-number-needed-to-treat
Updated: 2026-11-15
Published: 2026-09-16

[← Research](https://buythisglp.com/research)

Evidence

# GLP-1 Number Needed to Treat: 66 for One Major Cardiovascular Event

A review of 21 trials estimated how many people would need treatment to prevent one additional cardiovascular event.

Editorial profile: [Wesley Jenkins](https://buythisglp.com/authors/wesley-jenkins)[Buy This GLP Editorial Team](https://buythisglp.com/about)September 20266 min readUpdated November 2026

People treated per additional event prevented · major cardiovascular event · 66 · one death, any cause · 121 · cardiovascular death · 170 · Mean follow-up across trials: 2.4 years

**Research, not medical advice.** Buy This GLP is independent and educational. Nothing here is a substitute for individualized care from a licensed clinician, and reading it creates no doctor–patient relationship. Talk to your own provider before starting, stopping, or changing any medication, peptide, or therapy. See our [methodology](https://buythisglp.com/methodology) and [terms](https://buythisglp.com/terms).

## Key takeaways

-   A review of 21 randomized trials estimated a number needed to treat of 66 to prevent one additional major cardiovascular event.
-   The trials included 99,599 people and followed participants for an average of 2.4 years across the studies.
-   The number describes a group. It depends on the outcome, baseline risk, and follow-up.

The number needed to treat estimates how many people receive treatment for one additional outcome to be prevented compared with a control group. The guide to [what the SELECT trial counted as a cardiovascular event](https://buythisglp.com/research/do-glp1-drugs-prevent-heart-attacks) gives an example. A combined outcome includes events beyond heart attacks.[\[1\]](https://buythisglp.com/research/glp1-number-needed-to-treat#ref-1)

## What the pooled trials found

The review included 21 randomized trials of eight medications, including tirzepatide. Average follow-up across the trials was 2.4 years. The estimated number needed to treat was 66 for a trial-defined major cardiovascular event (incidence rate ratio 0.87, 95% CI 0.83–0.91). It was 121 for death from any cause and 170 for cardiovascular death.[\[1\]](https://buythisglp.com/research/glp1-number-needed-to-treat#ref-1)

The same review found more gastrointestinal and gallbladder disorders in the treatment groups. The separate analysis of [gallstones and reflux in randomized trials](https://buythisglp.com/research/glp1-gallstones-and-reflux-pooled) reports how those outcomes changed in absolute terms. They are different outcomes from those used to calculate the cardiovascular estimate.[\[1\]](https://buythisglp.com/research/glp1-number-needed-to-treat#ref-1)

## Why baseline risk and follow-up matter

The authors calculated these figures from absolute risk differences. One fewer event per 66 people compares the total number of events between groups. It does not identify which people benefited or capture other outcomes. A lower starting risk can mean a smaller absolute benefit even when the relative effect is the same.[\[1\]](https://buythisglp.com/research/glp1-number-needed-to-treat#ref-1)

Participants included people with cardiovascular disease or risk factors such as diabetes, obesity, or kidney disease. Different studies used different follow-up periods and definitions of cardiovascular events. The pooled result should be read with those differences in mind.[\[1\]](https://buythisglp.com/research/glp1-number-needed-to-treat#ref-1)

## Frequently asked

What does a number needed to treat of 66 mean?

In the pooled trial populations, the authors estimated one fewer major cardiovascular event per 66 people assigned treatment compared with control over the follow-up studied.

Does the estimate of 66 apply to an individual?

It describes a group and depends on the outcome, baseline risk, and length of follow-up. It cannot predict an individual’s benefit.

## Sources

1.  \[1\] Galli M, et al. (2025). Cardiovascular Effects and Tolerability of GLP-1 Receptor Agonists: A Systematic Review and Meta-Analysis of 99,599 Patients Journal of the American College of Cardiology. [PMID 40892610](https://www.jacc.org/doi/10.1016/j.jacc.2025.08.027)

## Where to get it

### Price the injectable sellers

The desk lists every seller that publishes an injectable figure, with the advertised price struck against the one a buyer is billed.

[Open the price desk →](https://buythisglp.com/)

## More in Evidence

-   [
    
    50,678 adults with a BMI of 30 or more · Prescribed · 8.0% · Filled · 4.4% · Outlined bar runs to 10%. Medicaid had lower odds of both.
    
    ### Does Medicaid Cover Weight Loss Drugs? It Depends on Your State
    
    ](https://buythisglp.com/research/does-medicaid-cover-weight-loss-drugs)
-   [
    
    What the claim rests on · Sleep study · AHI 15 or more · Obesity · BMI 30 or more · Prescription · for sleep apnea · Part D claim · plan review · Trial thresholds shown. Your plan sets its approval requirements.
    
    ### Does Medicare Cover Zepbound for Sleep Apnea? The Diagnosis Is the Key
    
    ](https://buythisglp.com/research/does-medicare-cover-zepbound-for-sleep-apnea)
-   [
    
    Illustrative decline with a one-week half-life · Ozempic window: up to 5 days late · 100% · day 0 · 82% · day 2 · 67% · day 4 · 61% · day 5 · 50% · day 7 · A calculation from the label half-life, not a blood test.
    
    ### What Happens If You Miss a Dose of Ozempic? A Week-Long Half-Life Buys Time
    
    ](https://buythisglp.com/research/what-happens-if-you-miss-a-dose-of-ozempic)
